文献速递胸部肿瘤

EGFR L858M/L861Q顺式突变对阿法替尼表现出选择性敏感性

EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
PubMed 文献 · J Thorac Oncol · 2017-01-11

该研究在一例NSCLC患者的肿瘤中检测到EGFR L858M/L861Q顺式突变,患者对厄洛替尼原发耐药,接受阿法替尼治疗后肿瘤退缩。体外实验显示第一、三代TKI对L858M/L861Q细胞的EGFR磷酸化抑制和增殖抑制能力低于L858R突变细胞,而阿法替尼在相似浓度下对两者均有抑制作用。

要点

  • EGFR L858M/L861Q顺式突变患者对厄洛替尼原发耐药,阿法替尼治疗后肿瘤退缩。
  • 体外实验中第一、三代TKI对L858M/L861Q细胞的抑制作用低于L858R突变细胞。
  • 阿法替尼在相似浓度下抑制L858M/L861Q和L858R突变细胞的增殖与EGFR磷酸化。

核心结论

  • 阿法替尼可能对携带罕见EGFR突变的肺癌患者是有益的治疗选择。
  • 了解罕见突变如何影响蛋白结构和TKI结合对识别有效靶向治疗很重要。

研究设计与样本

  • 对一例肺腺癌患者的肿瘤样本进行下一代测序,发现罕见的顺式EGFR突变。
  • 建立携带该突变的稳定Ba/F3和NIH-3T3细胞系,用MTS法检测细胞增殖、Western blotting检测EGFR磷酸化,研究第一、二、三代EGFR TKI的效果。

主要发现

  • 在一例NSCLC患者肿瘤中检测到EGFR L858M/L861Q顺式突变,患者对厄洛替尼原发耐药,后续阿法替尼治疗引起肿瘤退缩。
  • 体外研究中,与携带常见EGFR L858R点突变的细胞相比,第一、三代TKI对EGFR L858M/L861Q细胞的EGFR磷酸化抑制和增殖抑制能力降低。
  • 阿法替尼在相似浓度下降低L858M/L861Q和L858R突变细胞的增殖并抑制EGFR磷酸化。

临床怎么用

  • 作者认为阿法替尼可能对携带罕见EGFR突变的肺癌患者是有益的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have been developed to treat patients with EGFR-mutant lung cancers. However, the therapeutic efficacy of TKIs in patients with uncommon EGFR mutations remains unclear. METHODS: Next-generation sequencing was performed on a patient's lung adenocarcinoma tumor sample, revealing rare combined in cis (on the same allele) EGFR mutations. Stable Ba/F3 and NIH-3T3 cell lines harboring the mutations were established to investigate the effect of first-, second-, and third-generation EGFR TKIs on cell proliferation by MTS assay and EGFR phosphorylation by Western blotting. RESULTS: EGFR L858M/L861Q mutations in cis were detected in the tumor of a patient with NSCLC. The patient demonstrated primary resistance to erlotinib and was subsequently treated with afatinib, which caused tumor regression. In in vitro studies, first- and third-generation TKIs exhibited a decreased capacity to prevent EGFR phosphorylation and inhibit cell proliferation in EGFR L858M/L861Q cells compared with cells harboring the common EGFR L858R point mutation. In contrast, afatinib treatment reduced proliferation and inhibited EGFR phosphorylation in L858M/L861Q- and L858R-mutant cells at similar concentrations. CONCLUSIONS: Afatinib may be a beneficial therapeutic option for a subset of patients with lung cancer who harbor rare EGFR mutations in their tumors. Understanding how uncommon mutations affect protein structure and TKI binding will be important for identifying effective targeted therapies for these patients.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Saxon JA, Sholl LM, Jänne PA, et al. EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib. J Thorac Oncol. 2017. PMID: 28088511. doi:10.1016/j.jtho.2017.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。